| Outcome Measures: |
Primary: Change in HbA1c (%) from baseline to week 24, The change of HbA1c from baseline to 24 weeks compared with metformin hydrochloride + placebo, baseline, 24 weeks | Secondary: Percentage of HbA1c ≤ 6.5%, Proportion of patients achieving HbA1c ≤ 6.5% at week 24, 24 weeks|Percentage of HbA1c ≤ 7%, Proportion of patients achieving HbA1c ≤ 7% at week 24, 24 weeks|Change in HbA1c (%) from baseline to week 12, The change of HbA1c from baseline to 12 weeks compared with metformin hydrochloride + placebo, baseline, 12 weeks|Change in fasting plasma glucose (FPG) from baseline to week 12 and week 24, The change in FPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo, Baseline, 12 weeks and 24 weeks|Change in 2h-postprandial plasma glucose (2h-PPG) from baseline to week 12 and week 24, The change in 2h-PPG from baseline to week 12 and week 24 compared with metformin hydrochloride + placebo, Baseline, 12 weeks and 24 weeks|Change in body weight from baseline to week 12 and week 24, The change in body weight from baseline to week 12 and week 24 compared with metformin hydrochloride +placebo, Baseline, 12 weeks and 24 weeks
|
